Clinical Trials
24 trialsIPROC
Canadian Cancer Trials Group
PALEO
Australasian Gastro-Intestinal Trials Group
NEO-IMPACT
Australasian Gastro-Intestinal Trials Group
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
SLIDE-HCC
Canadian Cancer Trials Group
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Canadian Cancer Trials Group
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Canadian Cancer Trials Group
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Canadian Cancer Trials Group
CHESS
ETOP IBCSG Partners Foundation
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Canadian Cancer Trials Group
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
BOUNCE
ETOP IBCSG Partners Foundation
Chemo-free BRCA-targeted Neoadjuvant Strategy
European Organisation for Research and Treatment of Cancer - EORTC
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
SWOG Cancer Research Network
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
NSABP Foundation Inc
ILOC
European Organisation for Research and Treatment of Cancer - EORTC
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
NSABP Foundation Inc
SOLUTION
European Organisation for Research and Treatment of Cancer - EORTC